Vera Therapeutics (VERA) exec sells shares to cover RSU tax withholding

Rhea-AI Filing Summary

Vera Therapeutics SVP of Finance Joseph R. Young reported an open-market sale of 3,117 shares of Class A common stock on February 23, 2026, at a weighted-average price of $41.9839 per share. The shares were sold solely to cover tax withholding on vesting RSUs under a mandated sell-to-cover arrangement and were not a discretionary trade. After this transaction, Young directly held 64,722 shares.

Insider Trade Summary

Net Seller: 3,117 shares ($130,864)

Net Sell 1 txn

Insider Young Joseph R

Role SVP, FINANCE, CHIEF ACCT OFFCR

Sold 3,117 shs ($131K)

Type	Security	Shares	Price	Value
Sale	Class A Common Stock	3,117	$41.9839	$131K

Holdings After Transaction: Class A Common Stock — 64,722 shares (Direct)

Footnotes (1)

1. The trading order for shares sold to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs) of all participants for the Issuer, including the Reporting Person, occurred over a period of two (2) business days, beginning on February 23, 2026 and ending on February 24, 2026. Shares sold to solely satisfy tax withholding obligations incurred upon vesting of restricted stock units. The sale was mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell-to-cover" transaction and does not represent a discretionary trade by the reporting person. The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $41.005 to $42.84, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Young Joseph R

(Last) (First) (Middle)

C/O VERA THERAPEUTICS, INC.

2000 SIERRA POINT PARKWAY, SUITE 1200

(Street)

BRISBANE CA 94005

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Vera Therapeutics, Inc. [ VERA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, FINANCE, CHIEF ACCT OFFCR

3. Date of Earliest Transaction (Month/Day/Year)
02/23/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	02/23/2026(1)	02/24/2026	S(2)		3,117	D	$41.9839(3)	64,722	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The trading order for shares sold to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs) of all participants for the Issuer, including the Reporting Person, occurred over a period of two (2) business days, beginning on February 23, 2026 and ending on February 24, 2026.

2. Shares sold to solely satisfy tax withholding obligations incurred upon vesting of restricted stock units. The sale was mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell-to-cover" transaction and does not represent a discretionary trade by the reporting person.

3. The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $41.005 to $42.84, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.

	Joseph R. Young	02/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Vera Therapeutics (VERA) disclose in this Form 4 filing?

Vera Therapeutics disclosed that executive Joseph R. Young sold 3,117 shares of Class A common stock on February 23, 2026, at a weighted-average price of $41.9839 per share to cover tax withholding from vesting restricted stock units.

Why did the Vera Therapeutics (VERA) executive sell 3,117 shares?

The 3,117 shares were sold solely to satisfy tax withholding obligations from vesting restricted stock units. The sale was mandated by the company’s equity incentive plan as a sell-to-cover transaction and did not represent a discretionary trade by the executive.

What price did Vera Therapeutics (VERA) shares sell for in this insider trade?

The reported weighted-average sale price was $41.9839 per share. Footnotes state the shares were sold in multiple transactions at prices ranging from $41.005 to $42.84, and detailed trade information is available upon request from the reporting person.

How many Vera Therapeutics (VERA) shares does the insider hold after this sale?

After completing the tax-related sell-to-cover transaction, Joseph R. Young directly held 64,722 shares of Vera Therapeutics Class A common stock. This figure reflects his ownership immediately following the 3,117-share sale reported in the Form 4 filing.

Was the Vera Therapeutics (VERA) insider trade discretionary or pre-mandated?

The sale was not discretionary. It was mandated by Vera Therapeutics’ equity incentive plans, which require tax withholding obligations from vesting restricted stock units to be funded through a sell-to-cover transaction, according to the footnotes in the Form 4.